Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 7

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 7
---
 
     76,294  
     76,287  
     37,356 
  
    Stock-based compensation 
     304,946  
     96,289  
     4,431 
  
    Amortization of right-to-use operating lease asset 
     193,181  
     58,659  
     115,859 
  
    Share-based inducement expense 
     156,250  
     -  
     - 
  
    Amortization of debt discount 
     -  
     -  
     (1,875)
  
    Gain on revaluation of earnout and derivative liabilities 
     -  
     (1,800,000) 
     (320,117)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (289,715) 
     (670,064) 
     142,687 
  
    Accounts payable 
     727,912  
     (414,916) 
     128,429 
  
    Accrued liabilities 
     (299,690) 
     141,982  
     (50,370)
  
    Operating lease liability 
     (208,914) 
     (61,524) 
     (121,589)
  
    Net cash used in operating activities 
     (4,445,667) 
     (4,442,658) 
     (637,400)
  
    Cash flows from financing activities: 

    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     -  
     6,755,698  
     - 
  
    Advances from shareholder 
     -  
     13,731  
     - 
  
    Payment of sponsor loans 
     -  
     (19,715) 
     - 
  
    Proceeds from exercise of Series A Preferred Warrants 
     500,000  
     -  
     - 
  
    Proceeds from short term borrowings, net 
     -  
     408,052  
     - 
  
    Proceeds from share purchases under ELOC 
     1,227,241  
     -  
     - 
  
    Proceeds from collection of stock subscriptions